Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 3/20 | 0.52 |
| ▸ | PPARA | Q07869 | 2/20 | 0.52 |
| ▸ | CTSS | P25774 | 6/20 | 0.45 |
| ▸ | CTSK | P43235 | 5/20 | 0.45 |
| ▸ | APP | P05067 | 3/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1595057 | 1.00 | ATM (0.52) | ATMPPARGPPARACTSSCTSK | |
| SCHEMBL1742641 | 0.92 | ATM (0.52) | ATMPPARGPPARACTSSCTSK | |
| SCHEMBL2549240 | 0.92 | ATM (0.52) | ATMPPARGPPARACTSSCTSK | |
| SCHEMBL4659427 | 0.90 | ATM (0.50) | ATMPPARGPPARACTSSCTSK | |
| SCHEMBL14430204 | 0.90 | ATM (0.50) | ATMPPARGPPARACTSSCTSK | |
| SCHEMBL7356988 | 0.89 | ATM (0.54) | ATMCTSSCTSKAPPEPHX2 | |
| SCHEMBL5757257 | 0.88 | ATM (0.51) | ATMPPARGPPARACTSSCTSK | |
| SCHEMBL1519752 | 0.87 | FFAR2 (0.54) | ATMPPARGPPARACTSSCTSK | |
| SCHEMBL16384160 | 0.87 | PPARA (0.50) | ATMPPARGPPARACTSSCTSK | |
| SCHEMBL29163526 | 0.87 | FFAR2 (0.54) | ATMPPARGPPARACTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11638707-B2 | Substituted amino triazoles useful as chitinase inhibitors | MOLECURE S.A. (PL) | 2023-05-02 | — | — | US | disclosed |
| US-11638707-B2 | Substituted amino triazoles useful as chitinase inhibitors | MOLECURE S.A. (PL) | 2023-05-02 | — | — | US | disclosed |
| EP-3999500-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS CHITINASE INHIBITORS | OncoArendi Therapeutics S.A. (PL) | 2022-05-25 | — | — | EP | disclosed |
| US-20210015822-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS CHITINASE INHIBITORS | GALAPAGOS NV (BE) | 2021-01-21 | — | — | US | disclosed |
| WO-2021009209-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS CHITINASE INHIBITORS | Oncoarendi Therapeutics S.A. (PL) | 2021-01-21 | — | — | WO | disclosed |
| US-7919504-B2 | Thiadiazole modulators of PKB | AMGEN INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919504-B2 | Thiadiazole modulators of PKB | AMGEN INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919504-B2 | Thiadiazole modulators of PKB | AMGEN INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7897619-B2 | Heterocyclic modulators of PKB | AMGEN INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090298836-A1 | Thiadiazole modulators of PKB | AMGEN INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298836-A1 | Thiadiazole modulators of PKB | AMGEN INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298836-A1 | Thiadiazole modulators of PKB | AMGEN INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090275592-A1 | Heterocyclic modulators of PKB | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009011880-A2 | HETEROCYCLIC MODULATORS OF PKB | AMGEN INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009011871-A2 | THIADIAZOLE MODULATORS OF PKB | AMGEN INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298836-A1 | Thiadiazole modulators of PKB | PDK1, PDK2, MTOR | ATM 317/4885PPARG 361/4885PPARA 781/4885 |
| US-20090275592-A1 | Heterocyclic modulators of PKB | MTOR, PDK1, EIF4EBP1 | ATM 758/4885PPARG 549/4885PPARA 1396/4885 |
| US-20210015822-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS CHITINASE INHIBITORS | CHIT1, CHIA, CHI3L1 | ATM 543/4885PPARG 3658/4885PPARA 4350/4885 |
| US-11638707-B2 | Substituted amino triazoles useful as chitinase inhibitors | CHIT1, CHIA, CHI3L1 | ATM 543/4885PPARG 3658/4885PPARA 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.